HRP20181343T1 - Postupci i pripravci za induciranje imunosnog odgovora na egfrviii - Google Patents

Postupci i pripravci za induciranje imunosnog odgovora na egfrviii

Info

Publication number
HRP20181343T1
HRP20181343T1 HRP20181343TT HRP20181343T HRP20181343T1 HR P20181343 T1 HRP20181343 T1 HR P20181343T1 HR P20181343T T HRP20181343T T HR P20181343TT HR P20181343 T HRP20181343 T HR P20181343T HR P20181343 T1 HRP20181343 T1 HR P20181343T1
Authority
HR
Croatia
Prior art keywords
egfrviii
preparations
procedures
immune response
inducing immune
Prior art date
Application number
HRP20181343TT
Other languages
English (en)
Croatian (hr)
Inventor
Peter M. Lauer
Keith Bahjat
Original Assignee
Aduro Biotech, Inc.
Providence Health & Services-Oregon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech, Inc., Providence Health & Services-Oregon filed Critical Aduro Biotech, Inc.
Publication of HRP20181343T1 publication Critical patent/HRP20181343T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20181343TT 2010-11-17 2011-11-17 Postupci i pripravci za induciranje imunosnog odgovora na egfrviii HRP20181343T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41485010P 2010-11-17 2010-11-17
PCT/US2011/061164 WO2012068360A1 (en) 2010-11-17 2011-11-17 Methods and compositions for inducing an immune response to egfrviii
EP11841347.5A EP2640842B1 (en) 2010-11-17 2011-11-17 Methods and compositions for inducing an immune response to egfrviii

Publications (1)

Publication Number Publication Date
HRP20181343T1 true HRP20181343T1 (hr) 2018-10-19

Family

ID=46084412

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181343TT HRP20181343T1 (hr) 2010-11-17 2011-11-17 Postupci i pripravci za induciranje imunosnog odgovora na egfrviii

Country Status (17)

Country Link
US (3) US9200057B2 (enExample)
EP (1) EP2640842B1 (enExample)
JP (1) JP5998370B2 (enExample)
CN (1) CN103415620B (enExample)
CA (1) CA2818353A1 (enExample)
CY (1) CY1120622T1 (enExample)
DK (1) DK2640842T3 (enExample)
ES (1) ES2684684T3 (enExample)
HR (1) HRP20181343T1 (enExample)
HU (1) HUE039747T2 (enExample)
LT (1) LT2640842T (enExample)
PL (1) PL2640842T3 (enExample)
PT (1) PT2640842T (enExample)
RS (1) RS57630B1 (enExample)
SI (1) SI2640842T1 (enExample)
SM (1) SMT201800444T1 (enExample)
WO (1) WO2012068360A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SMT201800444T1 (it) * 2010-11-17 2018-09-13 Aduro Biotech Inc Metodi e composizioni per indurre una risposta immunitaria contro egfrviii
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
WO2013185052A1 (en) 2012-06-08 2013-12-12 Aduro Biotech Compostions and methods for cancer immunotherapy
HK1213008A1 (zh) 2012-11-06 2016-06-24 艾杜罗生物科技公司 兼性减毒细菌种类及其制备和使用方法
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
BR112015013440B1 (pt) 2012-12-13 2020-12-08 Aduro Biotech, Inc composições compreendendo dinucleotídeos de purina cíclicos com estereoquímicas
SG10201700916SA (en) 2012-12-27 2017-03-30 Aduro Biotech Inc Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
SI2996473T1 (sl) 2013-05-18 2019-12-31 Aduro Biotech, Inc. Sestavki in postopki za aktiviranje signaliziranja, odvisnega od "stimulator interferonskih genov"
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
KR102491332B1 (ko) * 2014-04-24 2023-01-27 어드박시스, 인크. 재조합 리스테리아 백신 균주 및 그 생산 방법
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
AU2015332524A1 (en) * 2014-10-14 2017-06-01 The Trustees Of The University Of Pennsylvania Recombinant Listeria vaccine strains and methods of using the same in cancer immunotherapy
US10688166B2 (en) 2014-11-03 2020-06-23 Cerus Corporation Compositions and methods for improved car-T cell therapies
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
CR20170507A (es) * 2015-04-13 2018-02-13 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos.
CA2982543A1 (en) * 2015-04-13 2016-10-20 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
US20160316247A1 (en) * 2015-04-27 2016-10-27 Ericsson Ab Program and device class entitlements in a media platform
WO2016191545A1 (en) * 2015-05-26 2016-12-01 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
CA2990570A1 (en) * 2015-06-24 2016-12-29 Advaxis, Inc. Manufacturing device and process for personalized delivery vector-based immunotherapy
CA3008641A1 (en) 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
WO2018026717A1 (en) * 2016-08-01 2018-02-08 Aduro Biotech, Inc. Protein expression enhancer sequences and use thereof
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
WO2021014398A1 (en) * 2019-07-23 2021-01-28 University Of Rijeka Faculty Of Medicine Integrated human cytomegalovirus / glioblastoma vaccine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
ATE262586T1 (de) * 1994-11-28 2004-04-15 Univ Jefferson Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
EP1401472A4 (en) * 2001-05-25 2005-04-06 Univ Jefferson ALTERNATIVE SPLICE FORMS OF PROTEINS AS A BASIS FOR MULTIPLE THERAPEUTIC MODALITIES
WO2003102168A1 (en) 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
AU2003259109A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Mesothelin vaccines and model systems
EP1592441B1 (en) 2003-02-06 2012-04-11 Aduro Biotech Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
JP4839209B2 (ja) 2003-02-06 2011-12-21 アンザ セラピューティクス，インコーポレイテッド 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
EP1940461B1 (en) * 2005-11-02 2014-01-08 Duke University Concurrent chemotherapy and immunotherapy
GB2451014B (en) * 2006-03-01 2010-12-29 Anza Therapeutics Inc Engineered Listeria comprising a modified ActA-antigen fusion protein and its use as a vaccine
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US8900816B2 (en) * 2007-07-19 2014-12-02 Duke University Assay for anti-EGFRvIII antibodies
US20110287055A1 (en) * 2008-05-19 2011-11-24 Aduro Biotech Compositions comprising prfa* mutant listeria and mehtods of use thereof
WO2010011870A2 (en) * 2008-07-24 2010-01-28 Anza Therapeutics, Inc. Compositions and methods for the treatment of hepatitis c
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
SMT201800444T1 (it) * 2010-11-17 2018-09-13 Aduro Biotech Inc Metodi e composizioni per indurre una risposta immunitaria contro egfrviii

Also Published As

Publication number Publication date
HUE039747T2 (hu) 2019-02-28
CY1120622T1 (el) 2019-12-11
US20140037662A1 (en) 2014-02-06
SMT201800444T1 (it) 2018-09-13
DK2640842T3 (en) 2018-08-13
US20160074491A1 (en) 2016-03-17
US9775891B2 (en) 2017-10-03
ES2684684T3 (es) 2018-10-04
SI2640842T1 (sl) 2018-09-28
EP2640842A1 (en) 2013-09-25
EP2640842A4 (en) 2014-04-09
PT2640842T (pt) 2018-10-12
US20180021420A1 (en) 2018-01-25
LT2640842T (lt) 2018-09-10
CA2818353A1 (en) 2012-05-24
PL2640842T3 (pl) 2018-11-30
US9200057B2 (en) 2015-12-01
EP2640842B1 (en) 2018-05-30
WO2012068360A1 (en) 2012-05-24
CN103415620A (zh) 2013-11-27
JP5998370B2 (ja) 2016-09-28
JP2014504851A (ja) 2014-02-27
RS57630B1 (sr) 2018-11-30
CN103415620B (zh) 2016-10-12

Similar Documents

Publication Publication Date Title
HRP20181343T1 (hr) Postupci i pripravci za induciranje imunosnog odgovora na egfrviii
IL265707A (en) Pharmaceutical preparations containing human antibodies to pcsk9
IL229663A0 (en) Algal lipid compositions and methods of preparing and utilizing same
HUE037140T2 (hu) Humán GDF8-hoz kötõdõ ellenanyagok
DK2844286T3 (da) Lyofiliserede og vandige anti-CD40-antistofformuleringer
SMT201900181T1 (it) Metodi di preparazione di coniugati
HUE045656T2 (hu) PHF-tau elleni ellenanyagok és alkalmazásuk
DK2914633T3 (da) Antistof/lægemiddel-konjugater og anvendelsesfremgangsmåder
HUE053720T2 (hu) ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
EP2598120A4 (en) COMPOSITIONS AND METHOD FOR CREATING AN IMMUNO TOLERANCE
HRP20190109T1 (hr) Ljudska antitijela na gfr 3 i načini za njihovu primjenu
EP2734049A4 (en) PROBIOTIC COMPOSITIONS AND METHOD
PT2888284T (pt) Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
IL230838A0 (en) Pharmaceutical compositions
PL2888593T3 (pl) Przeciwciała przeciwko rysperydonowi i ich zastosowanie
EP2888287A4 (en) ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE
EP2931313A4 (en) Solution Formulations of Genetically Engineered Anti- 23P19 Antibodies
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
IL235968B (en) Polysaccharide compositions and methods of use
CO7010828A2 (es) Preparación farmacéutica que comprende ߖciclodextrina sustituida
CO6990713A2 (es) Preparaciones que comprenden emodépsido amorfo
CR20130375A (es) Preparaciones que contienen antraquinona/formulaciones de lignina
PL2908833T3 (pl) Preparaty zawierające wyciągi ziołowe
EP2931042A4 (en) ANTHRACYCLINFORMULIERUNGEN
EP2895186A4 (en) THERAPEUTIC COMPOSITIONS AND RELATED METHODS